Teva Pharmaceutical Industries Ltd (ADR) Share Price Nasdaq
Stocks
US8816242098
Pharmaceuticals
OTC Markets Traded| Market Cap | 43.22B 37.24B 35.26B 31.96B 59.96B 4,129B 60.26B 419B 161B 2,101B 162B 159B 6,638B | P/E 2026 * |
53.1x | P/E 2027 * | 21.9x |
|---|---|---|---|---|---|
| Enterprise Value | 55.12B 47.49B 44.97B 40.76B 76.47B 5,266B 76.86B 534B 205B 2,679B 207B 202B 8,466B | EV / Sales 2026 * |
3.32x | EV / Sales 2027 * | 3x |
| Free-Float |
88.59% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript : Teva Pharmaceutical Industries Ltd (ADR)
| Manager | Title | Age | Since |
|---|---|---|---|
Richard Francis
CEO | Chief Executive Officer | 57 | 31/12/2022 |
Eli Kalif
DFI | Director of Finance/CFO | 53 | 21/12/2019 |
Matthew Shields
COO | Chief Operating Officer | 52 | 02/06/2024 |
| Director | Title | Age | Since |
|---|---|---|---|
Amir Elstein
BRD | Director/Board Member | 69 | 31/12/2008 |
Sol Barer
CHM | Chairman | 78 | 05/02/2017 |
Rosemary Crane
BRD | Director/Board Member | 65 | 31/08/2015 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -.--% | -.--% | - | - | 43.22B | |
| -0.65% | -2.93% | +47.52% | +87.34% | 994B | |
| -0.29% | -3.51% | +48.78% | +63.27% | 640B | |
| +0.83% | +0.26% | +16.76% | +72.52% | 454B | |
| -0.38% | -3.59% | +28.24% | +35.57% | 337B | |
| -0.09% | -13.54% | +10.08% | +26.87% | 261B | |
| -0.43% | -2.48% | -2.07% | +11.48% | 246B | |
| -1.34% | -13.70% | +33.47% | +44.18% | 204B | |
| -3.44% | -7.51% | -20.08% | -59.58% | 190B | |
| -0.75% | -4.82% | +21.94% | +86.55% | 178B | |
| Average | -0.66% | -5.76% | +20.52% | +40.91% | 389.42B | |
| Weighted average by Cap. | -0.51% | -4.42% | +29.87% | +55.71% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 16.6B 14.3B 13.54B 12.28B 23.03B 1,586B 23.15B 161B 61.86B 807B 62.35B 60.98B 2,550B | 17.32B 14.92B 14.13B 12.81B 24.02B 1,654B 24.15B 168B 64.53B 842B 65.04B 63.61B 2,660B |
| Net income | 1.27B 1.1B 1.04B 943M 1.77B 122B 1.78B 12.35B 4.75B 61.96B 4.79B 4.68B 196B | 2.43B 2.1B 1.98B 1.8B 3.38B 232B 3.39B 23.57B 9.07B 118B 9.14B 8.94B 374B |
| Net Debt | 11.9B 10.26B 9.71B 8.8B 16.51B 1,137B 16.6B 115B 44.35B 579B 44.7B 43.72B 1,828B | 8.65B 7.45B 7.06B 6.4B 12B 827B 12.06B 83.84B 32.24B 421B 32.49B 31.78B 1,329B |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
